Edition:
United Kingdom

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

8.70USD
23 May 2018
Change (% chg)

$0.05 (+0.58%)
Prev Close
$8.65
Open
$8.50
Day's High
$8.75
Day's Low
$8.50
Volume
27,217
Avg. Vol
15,360
52-wk High
$11.90
52-wk Low
$3.90

Latest Key Developments (Source: Significant Developments)

Aldeyra Therapeutics Announces Q1 Loss Per Share $0.43
Tuesday, 15 May 2018 

May 15 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.43.Q1 EARNINGS PER SHARE VIEW $-0.39 -- THOMSON REUTERS I/B/E/S.QTRLY BASIC AND DILUTED NET LOSS PER SHARE $0.43.  Full Article

Aldeyra Therapeutics Announces Year End 2017 Financial Results
Thursday, 29 Mar 2018 

March 29 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES YEAR END 2017 FINANCIAL RESULTS.ALDEYRA THERAPEUTICS INC - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $42.9 MILLION AS OF DECEMBER 31, 2017.  Full Article

Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING.  Full Article

Aldeyra Therapeutics reports Q3 loss per share of $0.32
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.32.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.‍Cash, cash equivalents, and marketable securities were $47.9 million as of September 30, 2017​.  Full Article

Aldeyra ‍announcesd new data for ADX-102 from Phase 2 clinical trials
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra - ‍announced new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis​.Aldeyra Therapeutics Inc - ‍Aldeyra plans to commence phase 2B clinical testing of ADX-102 in dry eye disease in first half of 2018​.Aldeyra Therapeutics Inc - ‍ADX-102 generated clinically important responses statistically superior to vehicle in patients with allergic conjunctivitis​.Aldeyra Therapeutics Inc - ‍plans to commence Phase 3 clinical testing of ADX-102 in allergic conjunctivitis in first half of 2018​.  Full Article

ALDEYRA THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK
Tuesday, 14 Feb 2017 

Aldeyra Therapeutics Inc : ALDEYRA THERAPEUTICS INC PRICES PUBLIC OFFERING OF COMMON STOCK .SAYS PUBLIC OFFERING OF 2.22 MILLION COMMON SHARES PRICED AT $4.50 PER SHARE.  Full Article

Aldeyra Therapeutics Inc proposes public offering of common stock
Monday, 13 Feb 2017 

Aldeyra Therapeutics Inc :Aldeyra Therapeutics Inc proposes public offering of common stock.  Full Article

Aldeyra Therapeutics reports Q2 loss per share $0.41
Wednesday, 10 Aug 2016 

Aldeyra Therapeutics Inc : Aldeyra Therapeutics announces second quarter 2016 financial results and provides corporate update . Q2 loss per share $0.41 .Q2 earnings per share view $-0.44 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Aldeyra Therapeutics Appoints David Mcmullin As Senior Vice President, Corporate Development And Strategy

* ALDEYRA THERAPEUTICS APPOINTS DAVID MCMULLIN AS SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT AND STRATEGY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)